For Patients

Description

Nitof 7 mg is the final stage in your step-down quit plan. Used in weeks 9 to 12, it delivers a low dose of nicotine to gently taper your body off dependence and minimize relapse risk.

Ingredients

Active: Active: Nicotine USP - 7 mg

Inactive: Acrylic adhesive, release liner, polyester backing

Storage & Precautions

Site of Application

Apply on clean, dry, hairless skin (upper arm, chest, or back). Rotate the site with each new patch to avoid skin irritation.

Dosage & Administration

• Apply 1 patch every 72 hours (3 days)
• Use Nitof 7 mg for weeks 9 to 12 of your 12-week quit program

Benefits

• Supports final nicotine reduction
• Encourages full quit confidence
• No smoke, smell, or social awkwardness
• 3-day patch cycle reduces daily routine hassles

Clinical Overview

Nitof 7 mg is a low-dose nicotine patch formulated for the final stage of nicotine withdrawal. It is intended for patients who have successfully completed earlier stages of NRT (21 mg and 14 mg). This patch supports long-term cessation by gradually eliminating nicotine dependence.

Ingredients & Composition

Active Ingredient: Active Ingredient: Nicotine USP - 7 mg delivered over 72 hours

Other Excipients: Medical-grade adhesive system and backing membrane

Mechanism of Action

Nitof 7 mg allows gentle tapering of nicotine delivery while preventing withdrawal flare-ups. This supports neurochemical adaptation and helps reduce the risk of relapse during the critical final weeks of therapy.

Indications

• Final taper dose in structured 12-week smoking cessation program
• For patients who completed 8 weeks of 21 mg and 14 mg treatment
• Smokers aiming for full nicotine discontinuation

Dosage & Administration

• Apply one Nitof 7 mg patch every 72 hours
• Recommended use: Weeks 9-12
• No further NRT required after completion

Site of Application

Use clean, dry skin on upper arm, back, or chest. Rotate site to prevent skin irritation

Pharmacokinetics

• Delivers sub-therapeutic nicotine levels to prevent sudden withdrawal
• Linear decline in systemic concentration over 72 hours
• Allows endogenous receptor reset and craving resistance

Contraindications & Warnings

• Avoid use in patients with known nicotine hypersensitivity
• Evaluate for anxiety or relapse risk as nicotine is fully tapered

Patient Suitability

Ideal for:

• Patients nearing completion of NRT
• Low-risk individuals without high relapse probability
• Those needing minimal support to maintain abstinence

Clinical Evidence

• Final tapering doses reduce relapse risk by up to 40% in structured quit programs
• NIH and Cochrane reviews support step-down therapy as superior to abrupt cessation
• Nitof 7 mg shows better skin tolerance and user satisfaction at the endpoint

Storage & Handling

• Store below 25°C
• Dispose of used patches responsibly
• Keep sealed until use to prevent drug loss

Supporting Tools & Resources

• “Final Step” completion guide
• Post-quit support checklist
• Clinic posters encouraging nicotine-free life
• MantraBot integration for post-quit reinforcement